The vaccine combined Immunovaccine’s DepoVax adjuvanting technology and Weill Cornell’s novel anti-cocaine vaccine (dAd5GNE).
Immunovaccine chief science officer Dr. Marc Mansour said the company’s delivery system holds the vaccine at the site of injection allowing the immune system to process the vaccine differently than other vaccines.
"This results in strong immunity against the target, in this case cocaine. The next time cocaine appears in the blood the subject’s immune system seizes the molecules and neutralizes their effect," Dr. Mansour added.
The DepoVax-enhanced vaccine produced high levels of target antibodies with potential to seize the cocaine in the blood of immunized mice and obstruct its transfer to the brain.